Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30406919 | 1.00 | PNMT (0.54) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL22910024 | 0.97 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL6192350 | 0.97 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL21447111 | 0.97 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL18746500 | 0.97 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL18746707 | 0.97 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL29576955 | 0.97 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT | |
| SCHEMBL1468326 | 0.95 | PNMT (0.54) | PNMTASIC3TSHRTDP1MAPT | |
| Hydrochloric Acid SCHEMBL28759209 | 0.92 | PNMT (0.52) | PNMTASIC3TDP1MAPTALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL4733194 | 0.92 | PNMT (0.52) | PNMTASIC3TSHRTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119751503-A | Method for preparing aryl phosphonic acid dialkyl ester by one-pot method | 苏州凯若利新材料科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| CN-115335365-B | Aminocyclobutane as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11919870-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-05 | — | — | US | disclosed |
| WO-2024044778-A2 | NOVEL MODULATORS OF FSHR AND USES THEREOF | CELMATIX INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| WO-1999033821-A1 | BENZOPYRAN AND BENZOTHIOPYRAN DERIVATIVES HAVING RETINOID ANTAGONIST-LIKE ACTIVITY | ALLERGAN SALES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998058922-A1 | SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES | ALLERGAN SALES, INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| US-5723620-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0800517-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5654469-A | FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-08-05 | — | — | US | disclosed |
| US-5591858-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity | ALLERGAN | 1997-01-07 | — | — | US | disclosed |
| US-5543534-A | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-08-06 | — | — | US | disclosed |
| WO-1996020930-A1 | ACETYLENES DISUBSTITUTED WITH A 5 OR 8 SUBSTITUTED TETRAHYDRONAPHTHYL OR DIHYDRONAPHTHYL GROUP AND WITH AN ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5514825-A | SYNTHETIC RETINOIDS | ALLERGAN, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| US-4216105-A | Compositions for the optical whitening of organic materials and use thereof | HICKSON & WELCH LIMITED (GB) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919870-B2 | Aminocyclobutanes as monoacylglycerol lipase modulators | MGLL, DAGLB, FAAH | PNMT 2611/4885ASIC3 1434/4885TSHR 679/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | PNMT 3489/4885ASIC3 2808/4885TSHR 68/4885 |
| US-20230331686-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | PNMT 2611/4885ASIC3 1434/4885TSHR 679/4885 |
| US-20240208914-A1 | AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, DAGLB, FAAH | PNMT 2611/4885ASIC3 1434/4885TSHR 679/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | PNMT 3623/4885ASIC3 3452/4885TSHR 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.